No Data
Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis
FDA accelerated approves Gilead's small molecule therapy for treating fatal liver disease.
Primary biliary cholangitis is a potentially life-threatening autoimmune liver disease. ALP is a cholestasis marker that can predict the risk of liver transplantation and death.
Maxim Group Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Gilead Sciences: A Strong Buy on Solid Financials and Promising R&D Pipeline
Gilead Sciences Insider Sold Shares Worth $406,150, According to a Recent SEC Filing
Gilead Wins FDA Nod for Liver Disease Drug
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
